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Reviewa b s t r a c t
The excess lung cancer risk from smoking declines with time quit, but the shape of the decline has never
been precisely modelled, or meta-analyzed. From a database of studies of at least 100 cases, we extracted
106 blocks of RRs (from 85 studies) comparing current smokers, former smokers (by time quit) and never
smokers. Corresponding pseudo-numbers of cases and controls (or at-risk) formed the data for ﬁtting the
negative exponential model. We estimated the half-life (H, time in years when the excess risk becomes
half that for a continuing smoker) for each block, investigated model ﬁt, and studied heterogeneity in H.
We also conducted sensitivity analyses allowing for reverse causation, either ignoring short-term quitters
(S1) or considering them smokers (S2). Model ﬁt was poor ignoring reverse causation, but much
improved for both sensitivity analyses. Estimates of Hwere similar for all three analyses. For the best-ﬁt-
ting analysis (S1), H was 9.93 (95% CI 9.31–10.60), but varied by sex (females 7.92, males 10.71), and age
(<50 years 6.98, 70+ years 12.99). Given that reverse causation is taken account of, the model adequately
describes the decline in excess risk. However, estimates of H may be biased by factors including mis-
classiﬁcation of smoking status.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction1
It has long been known that smoking increases lung cancer risk,
with the excess risk (i.e. the increase in relative risk (RR) compared
to never smokers) declining on quitting (US Surgeon General,
1979). In 2007, in a Monograph ‘‘reversal of risk after quitting
smoking’’ the International Agency on Research and Cancer (IARC)
(2007) examined the evidence in detail, noting that ‘‘within ﬁve to
nine years after quitting, the lower lung cancer risk in former com-
pared with otherwise similar current smokers becomes apparent
and diverges progressively with longer time since cessation. There
is a persistent increase in risk of lung cancer in former smokers
compared to never smokers of the same age, even after a long
duration of abstinence.’’ However, the time-pattern of the decline
in excess risk following quitting has never been precisely de-scribed, and published assessments of the evidence seem based
on an impression of how the estimated RR, and its 95% conﬁdence
interval (CI), varies by time quit, with no formal method used to ﬁt
curves to the declining pattern, or test whether patterns vary be-
tween studies. Here, we rectify this omission by ﬁtting, separately
for data sets satisfying deﬁned criteria, a simple model to the ob-
served decline. This model, the negative exponential, characterizes
the shape of the curve by a single parameter which can be used to
assess variation between studies. This parameter, the half-life (H),
is the time at which the excess risk of a quitter reaches half that of
a continuing smoker.
Although, for prospective studies, we do not estimate the abso-
lute risk of lung cancer in never smokers, the estimate of H is de-
rived from the pattern of declining excess risk (sometimes
referred to as excess relative risk) following quitting. Thus, if the
RR is, for example, 15 for current smokers, so that the excess risk
is 14, our interest is in estimating the time after quitting at which
the excess risk is 7 (or the RR is 8), and in estimating the excess risk
(and RR) at other time points since quitting. In Additional ﬁle 1:
‘‘Multistage’’ (downloadable from http://www.pnlee.co.uk/down-
loads/ieslc3/LC_Quitting_Paper_AdditionalFiles.htm), we demon-
strate that the predictions of the decline in excess risk following
quitting are quite similar to those of the multistage model, often
used for detailed analysis of individual subject data on smoking
and lung cancer (Brown and Chu, 1987; Doll and Peto, 1978;
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that estimates of H depend little on the assumed magnitude of
the excess risk in current smokers. Although, for a given current
smoker RR, estimates of H tend to be somewhat greater for popu-
lations with a longer duration of smoking, the negative exponential
model appears a useful simple method to summarize published
epidemiological data.
In this journal, we recently used the negative exponential model
to quantitatively review the evidence on the decline in excess risk of
ischaemic heart disease (IHD) following quitting smoking (Lee et al.,
2012b). Using 41 independent data blocks from 23 epidemiological
studies that compared risk in current smokers, never smokers and
quitters by time period of quit, we estimated H as 4.40 (95% CI
3.26–5.95) years. We also demonstrated how the model could be
adapted to estimate the decline in risk following cutting down the
amount smoked, or switching to a reduced exposure product.
Here we use the methodology described (Lee et al., 2012b) to
estimate H for lung cancer, to investigate model goodness-of-ﬁt,
and to study sources of variation in H. We also consider ‘‘reverse
causation’’, the tendency for smokers to quit shortly before diagno-
sis of the lung cancer as a result of associated precursor symptoms.
The data we use come from the International Evidence on Smoking
and Lung Cancer (IELSC) database, recently used (Lee et al., 2012a)
to carry out extensive meta-analyses based on 287 epidemiological
studies published before 2000 which involve 100 or more lung
cancer cases, a database we have updated to include more recent
papers. The meta-analyses for duration of quitting compared risk
in current smokers (or in never smokers) with risk in former smok-
ers who had quit for ‘‘about 3 years’’, ‘‘about 7 years’’ and ‘‘about
12 years’’, with attention restricted to RRs for quit periods which
included one key year (3, 7 or 12), but no other. That approach is
limited, as only those quit periods including precisely one key year
are considered, and because results for the same key year may re-
late to differing quit periods in different studies. Also, the overall
estimates for the different key years come from different sets of
studies, as some provide results for only one or two key years. Also,
no formal attempt was made to describe the shape of the relation-
ship of risk to time quit. A model-ﬁtting approach, as described
here, is in principle a better way to summarize results. At this
stage, we have only applied it to results for overall lung cancer risk,
with no attempt made to ﬁt models for speciﬁc histological types.2. Methods
2.1. The IESLC database
The IELSC database has been fully described earlier (Lee et al.,
2012a). Papers considered had to be published before 2000, de-
scribe studies of 100+ cases, and provide RR estimates for one or
more indices of smoking (note that we use the term RR generically
to describe alternative estimates of the relative risk, such as the
odds ratio or hazard ratio). Data on time quit from more recently
published papers have been added, using the same data entry
procedures.2.2. Additional literature searching
Part of our regular in-house system for collecting papers of po-
tential interest involves routinely coding papers on certain issues
in relation to whether they provide data for a future IESLC update
as: IESLCY = relevant, IESLCNN = not relevant as less than 100
cases, IESLCN = not relevant for other reasons, and IESLCQ = rele-
vance to be decided. Papers cited in our earlier review (Lee et al.,
2012a) were coded IESLCYD. In October 2011 we carried out a
MedLine search on ‘‘Smoking and Lung Cancer’’ restricted to paperspublished since 1998, aimed at identifying further studies relevant
to an update of IESLC. These papers were cross-checked against
those already on our in-house system, those coded IESLCYD being
ignored, as being already dealt with. Other papers on our system
not previously coded IESLCY or IESLCQ were coded IESLCQ. All pa-
pers coded IESLCQ were then examined, and given an IESLCY, IES-
LCNN or IESLCN code. Abstracts of papers not previously on our
system were then examined. Attempts were then made to obtain
papers considered relevant, and also some additional papers iden-
tiﬁed from the IARC cessation review (International Agency for Re-
search on Cancer, 2007). Papers obtained were then examined and
coded. Finally all papers coded IESLCY were examined to see
whether they reported results for time quit, particularly results
comparing risk in current smokers, never smokers and multiple
year of quit groups.
2.3. Data selection and blocks
All the results considered concerned blocks of RRs for all lung
cancer (or occasionally near equivalent deﬁnitions which each in-
cluded the major histological types squamous cell carcinoma and
adenocarcinoma). Each block usually consisted of RR and 95% CI
estimates, expressed relative to never smokers, for former smokers
(by time quit) and for current smokers (considered to have time
quit zero). Sometimes RRs were provided relative to current smok-
ers, for former smokers (by time quit) and for never smokers.
Where possible, blocks were considered separately by sex and
age. RRs adjusted for covariates were preferred to unadjusted
RRs. However, RRs for former vs. current smokers which were ad-
justed for other aspects of smoking could not be considered as we
required comparable results for never smokers. For each block, the
data recorded included study type, sex, location, year of publica-
tion, age range (at baseline for prospective studies), deﬁnition of
product smoked (any product, cigarettes +/ other products [i.e.
pipes or cigars], cigarettes only), deﬁnition of never smoker (never
any product, never cigarettes [i.e. may include pipe/cigar only
smokers]). For each RR in the block, the range of each quitting per-
iod was also recorded.
2.4. Pseudo-numbers
A ﬁrst analysis step was to use the method of Hamling et al.,
(2008) on each block to estimate the pseudo-table of the numbers
of cases and either the numbers of controls (for case-control stud-
ies) or the numbers in the at risk population (for prospective stud-
ies) that correspond to the observed RRs and 95% CIs. The method
was applied even when the RRs were unadjusted for covariates.
This estimation requires, in addition to the given RRs and 95%
CIs, estimates of the proportion of never smokers among the con-
trols/at risk and of the ratio of total controls/at risk to total cases,
as well as starting estimates for the numbers of never smoking
cases and controls/at risk. These estimates were also recorded on
the database. The pseudo-table forms the basic data for ﬁtting
the negative exponential model.
Where RRs were expressed relative to current, rather than
never, smokers the additional information entered, apart from
the ratio of total controls/at risk to total cases, was the proportion
of current, rather than never, smokers, among the controls/at risk
and starting estimates for the numbers of current smoking cases
and controls/at risk. The pseudo-numbers can also be used to re-
express these RRs relative to never smokers.
2.5. Midpoints for levels of exposure
Midpoint estimates were derived as for the IHD analyses (Lee
et al., 2012b). For closed intervals, this was the mean of the limits
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mean of the lower limit and either 50 years or the upper limit of
the population age range studied minus 20 years, if this was smal-
ler than 50 years. The midpoint time quit for current smokers was
always taken as zero, even if short-term quitters were combined
with current smokers.
2.6. The negative exponential model
The methods used were as for IHD (Lee et al., 2012b), and in-
volved maximum likelihood methods to estimate H (in years)
and its SE.
For prospective studies, the underlying model ﬁtted to a block
was:
Pj ¼ Aþ B exp ðCtjÞ
where Pj is the absolute risk of lung cancer for time quit tj in group j
and A, B and C are parameters to be estimated. Here A is the risk in
never smokers (tj = inﬁnite) and B is the excess absolute risk in cur-
rent smokers (tj = 0). The term exp (Ctj) models the proportional
decline in excess absolute risk for quitters, declining asymptotically
from 1 to 0, as time increases. H is estimated by:
0:5 ¼ exp ðCHÞ
or
H ¼ ðloge2Þ=C
For case-control studies, the model used is:
F j ¼ 1þ B exp ðCtjÞ
where Fj is the RR (compared to never smokers) rather than the
absolute risk and H is estimated as before. While C (and thus H)
has the same interpretation as it has for prospective studies, the
interpretation of B is different, being the excess relative rather than
excess absolute risk.
For both prospective and case-control studies the method, de-
scribed fully elsewhere (Lee et al., 2012b), allows estimation of
the ﬁtted RRs and numbers of cases and controls/at risk by level
corresponding to the observed RRs and (pseudo-) numbers, and
testing for goodness-of-ﬁt by an approximate chi-squared statistic.
2.7. Regression analyses
Sources of heterogeneity were studied by inverse-variance
weighted regression of log H. Between block variation was exam-
ined one factor at a time (simple regression), and also using for-
ward stepwise methods. The factors used were study type, sex,
location, publication year, midpoint age of the subjects (at baseline
for prospective studies), smoking product, study size, and current
smoker RR. The deviance of the ﬁtted models was used to indicate
the extent to which the heterogeneity was explained. The esti-
mates of log H and its SE were back transformed to give estimates
of H with 95% CI.
2.8. Sensitivity analyses
Two different sensitivity analyses were conducted to study the
dependence of H on reverse causation. In sensitivity analysis S1,
RRs for quitters relating to the shortest quit time were omitted
from each block. In sensitivity analysis S2, all RRs for quitters in
each block relating to a range of quit times with upper limit at
most three years were considered to be current smokers, the pseu-
do-numbers for those RRs being combined with those for the cur-
rent smoking RR.2.9. Statistical signiﬁcance
No adjustments were made for multiple testing, with signiﬁ-
cance deﬁned as p < 0.05. However, results showing stronger evi-
dence of a relationship (p < 0.01, or p < 0.001), or in some cases
weaker evidence of signiﬁcance (p < 0.1) are also distinguished,
where appropriate.
2.10. Software
All data entry and most statistical analyses were carried out
using ROELEE version 3.1 (available from P.N.Lee Statistics and
Computing Ltd., 17 Cedar Road, Sutton, Surrey SM2 5DA, UK). Some
analyses were conducted using Excel 2003.3. Results
3.1. Additional papers and studies identiﬁed
Our earlier review (Lee et al., 2012a) identiﬁed 5993 potentially
relevant publications. Of these, 678 satisﬁed the IESLC inclusion
criteria, providing information on 287 studies, 267 principal stud-
ies and 20 subsidiary (as deﬁned in that review (Lee et al., 2012a)).
Table 1 presents a detailed ﬂow chart of the search for additional
papers relevant to a possible future IESLC update, and to providing
additional data on time quit. From the routine searching we con-
ducted since our earlier review looking for papers of interest on
smoking and health, 509 papers were coded as relevant (IESLCY)
to an update, and 123 as possibly relevant (IESLCQ). The Medline
search carried out in October 2011 identiﬁed 7259 papers as pos-
sibly relevant to an IESLC update. Of these 1321 were already on
our in-house system, and rejecting those already in IESLC or previ-
ously coded irrelevant, an additional 339 papers were coded IES-
LCQ. After examining all 462 papers now coded IESLCQ, 34 were
recoded IESLCY, giving a total of 543 based on papers already in-
house when the Medline search was conducted.
Of the 7259 papers, 5938 were not already in house. Of these,
5271 were rejected as irrelevant to an IESLC update based on the
abstract. We ordered the remaining 667 papers and an additional
15 cited in the IARC review (International Agency for Research
on Cancer, 2007), and could obtain copies of 642 of the total of
682. Of these 642, 306 were then coded IESLCY, increasing the
number from 543 to 849.
Of the 849 papers, 125 (from 129 studies) provided data on risk
by time quit. However, only 58 of the studies provided the required
complete block of data, comparing current smokers, quitters (by
time quit) and never smokers. The rest provided data that could
not be modelled, such as average age of quit in cases and controls.
Additional ﬁle 2: ‘‘Studies’’ (downloadable from http://www.
pnlee.co.uk/downloads/ieslc3/LC_Quitting_Paper_AdditionalFiles.
htm) gives brief details of each of the 85 studies providing the data
used for the modelling, including the six character study reference
code (REF); a brief study description including the location, main
characteristics of the study population, study design and study
duration; the total number of lung cancers studied; and data
sources.
3.2. The data blocks
Table 2 gives some details of the 106 blocks considered in anal-
ysis, ﬁve having been rejected as being based on less than 10 quit-
ters. These blocks derived from 85 studies, 64 providing only one
block, 20 one block for each sex, and one (DORN) a block for each
of two age groups. Sixty two (58.5%) blocks are for males, 27
(25.5%) for females and 17 (16.0%) where risk was not separately
Table 1
Identifying additional data on time quit.
7259 papers identified from Medline search in October 2011 for possible 
relevance to an IESLC update
1321 papers already on our 
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America, 32 (30.2%) from Europe, 19 (17.9%) from Asia, 11
(10.4%) from South or Central America, 3 (2.8%) from Australasia,
and 1 (0.9%) from a multi-country study. Twenty eight (26.4%)
blocks are from prospective studies and 78 (73.6%) from case-con-
trol studies. The most common exposed/unexposed comparisons
are ‘‘any product vs. never any product’’ (40 blocks, 37.7%) and
‘‘cigarettes +/ other products vs. never cigarettes’’ (35 blocks,33.0%). Of the 17 blocks for the sexes combined, 9 (52.9%) concern
RRs adjusted for sex. Sixty three of the 106 blocks (59.4%) concern
RRs adjusted for age, 4 (3.8%) RRs adjusted for race, and 42 (39.6%)
RRs adjusted for other factors, as given in the footnotes to Table 2.
Table 3 gives the RRs for each block. Data are shown ﬁrst for the
group considered current smokers in analysis (with mean quit time
0), and then for the former smokers by increasing time of quit. In
52 blocks, as indicated in the column ‘‘time quit groupings’’,
Table 2
Time quit – details of the 106 blocks used.
Block: study Sexa Study typeb Locationc Productd Unexposede Adjustedf Current smoker RR Cases in quittersg
1:ALDERS M C-C Europe Cigarettes only Never any Age 10.0000 177.9671
2:ALDERS F C-C Europe Cigarettes only Never any Age 4.5500 285.3709
3:ANDERS F Prosp NAmer Cigarettes +/ Never cigs Age +6 18.6700 119.7367
4:ARMADA M C-C Europe Cigarettes +/ Never cigs None 13.6762 129.0000
5:BARBON M C-C Europe Any product Never any Age 13.8000 163.3704
6:BAYSSO C C-C Europe Any product Never any Sex, age +1 15.6000 167.7297
7:BECHER M C-C Europe Any product Never any None 14.9016 42.0000
8:BHURGR C C-C Asia Any product Never any Sex, age +1 33.3333 86.6911
9:BROSS M C-C NAmer Cigarettes +/ Never any None 5.9195 212.0000
10:BRUSKE M C-C Europe Cigarettes +/ Never any None 33.1094 213.0000
11:CAICOY C C-C Europe Any product Never any None 5.0029 131.0000
12:CARPEN C C-C NAmer Cigarettes +/ Never cigs None 32.8939 86.0000
13:CEDERL M Prosp Europe Any product Never any Age 7.8100 15.1355
14:CHOI M C-C Asia Cigarettes +/ Never cigs None 5.1309 38.0000
15:CHYOU M Prosp NAmer Cigarettes +/ Never cigs Age +1 10.3300 28.2125
16:CPSI M Prosp NAmer Cigarettes only Never any Age 13.7700 133.9100
17:CPSII M Prosp NAmer Cigarettes only Never any Age 19.6900 1579.9939
18:CPSII F Prosp NAmer Cigarettes +/ Never cigs Age 12.9700 262.2903
19:DAMBER M C-C Europe Any product Never any Age 9.6000 128.3371
20:DEAN3 M C-C Europe Any product Never any Age 6.0100 85.3157
21:DESTE3 C C-C SCAmer Any product Never any None 11.1903 286.0000
22:DESTE4 M C-C SCAmer Any product Never any None 12.6014 219.0000
23:DESTEF M C-C SCAmer Any product Never any Age +3 10.9000 112.8312
24:DOLL M C-C Europe Any product Never any None 9.5173 70.0000
25:DOLL F C-C Europe Any product Never any None 2.0866 10.0000
26:DOLL2 M Prosp Europe Cigarettes only Never any Age 15.8000 33.8626
27:DORGAN M C-C NAmer Cigarettes +/ Never any None 16.5270 242.0000
28:DORGAN F C-C NAmer Cigarettes +/ Never any None 10.5980 166.0000
29:DORN M/55–64 Prosp NAmer Cigarettes +/ Never any None 13.5159 94.0000
30:DORN M/65–74 Prosp NAmer Cigarettes +/ Never any None 9.0254 118.0000
31:EPIC M Prosp Europe Any product Never any Age +1 19.5200 73.3071
32:EPIC F Prosp Europe Any product Never any Age +1 6.4500 30.1596
33:FIELD F C-C NAmer Cigarettes +/ Never cigs None 25.9777 103.0000
34:FRANCO M C-C SCAmer Any product Never any Age +2 7.6923 87.7845
35:FRANCO F C-C SCAmer Any product Never any Age +2 3.4483 19.7054
36:GAJALA M C-C Asia Any product Never any Age +4 5.2632 89.6005
37:GAO M C-C Asia Cigarettes +/ Never cigs Age +1 3.9000 123.2021
38:GAO F C-C Asia Cigarettes +/ Never cigs Age +1 2.9000 73.3339
39:GAO2 M C-C Asia Cigarettes +/ Never cigs None 6.7745 83.0000
40:GARSHI M C-C NAmer Any product Never any Age 7.7000 291.8021
41:GRAHAM M C-C NAmer Cigarettes +/ Never any Age 7.2600 152.2682
42:HAMMO2 M Prosp NAmer Cigarettes +/ Never any Age 10.1400 92.4092
43:HIRAYA M Prosp Asia Cigarettes +/ Never any Age 4.4500 22.4818
44:IARC M C-C Europe Cigarettes only Never cigs Age +2 25.0000 1604.2946
45:IARC F C-C Europe Cigarettes only Never cigs Age +2 9.0909 209.7387
46:JACOBS M Prosp Multi Cigarettes +/ Never any Age +1 3.9500 35.2945
47:JAIN M C-C NAmer Cigarettes +/ Never cigs None 15.9075 126.0000
48:JAIN F C-C NAmer Cigarettes +/ Never cigs None 12.6787 85.0000
49:JAMRO1 F Prosp Auslia Any product Never any Age +4 21.9200 38.5093
50:JAMRO2 M Prosp Auslia Any product Never any Age +4 10.7400 210.0212
51:JOLY M C-C SCAmer Cigarettes +/ Never any None 15.6358 101.0000
52:JOLY F C-C SCAmer Cigarettes +/ Never any None 7.4832 34.0000
53:KAISE2 M Prosp NAmer Cigarettes only Never any Age 8.0000 24.2337
54:KAISE2 F Prosp NAmer Cigarettes only Never any Age 14.1400 12.7048
55:KHUDER M C-C NAmer Cigarettes +/ Never cigs None 10.4162 214.0000
56:KUBIK2 M C-C Europe Cigarettes +/ Never cigs Age +2 27.1900 176.0870
57:KUBIK2 F C-C Europe Cigarettes +/ Never cigs Age +2 7.7200 189.1969
58:LEE M C-C Asia Cigarettes +/ Never cigs Age +3 3.4500 12.9800
59:LEE2 C C-C NAmer Any product Never any Sex, age, race +1 3.7037 332.4212
60:LEITZM M Prosp NAmer Cigarettes +/ Never cigs Age +10 32.3700 2135.2046
61:LEITZM F Prosp NAmer Cigarettes +/ Never cigs Age +10 21.7200 872.0891
62:LUBIN M C-C Asia Cigarettes +/ Never any None 3.6431 70.0000
63:LUBIN2 M C-C Europe Cigarettes +/ Never any None 10.3834 1947.0000
64:LUBIN2 F C-C Europe Cigarettes +/ Never any None 3.7944 111.0000
65:MAO M C-C NAmer Cigarettes +/ Never cigs Age +5 17.3000 574.1720
66:MAO F C-C NAmer Cigarettes +/ Never cigs Age +5 13.2000 392.3272
67:MATOS M C-C SCAmer Cigarettes +/ Never any Age +1 10.0000 68.9876
68:OLSEN C C-C Europe Any product Never any Sex, age +1 21.2900 77.2620
69:OSAKI M Prosp Asia Any product Never any Age 4.9000 28.1389
70:PAPADO F C-C Europe Any product Never any None 6.8097 175.0000
71:PARK M C-C Asia Cigarettes +/ Never cigs Age +1 2.2727 133.0520
72:PARK F C-C Asia Cigarettes +/ Never cigs None 3.0769 15.0000
73:PETRAU M C-C Europe Any product Never any Age +1 20.0000 63.7030
74:PEZZO2 M C-C SCAmer Cigarettes +/ Never cigs None 22.9470 128.0000
(continued on next page)
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Table 2 (continued)
Block: study Sexa Study typeb Locationc Productd Unexposede Adjustedf Current smoker RR Cases in quittersg
75:PEZZOT M C-C SCAmer Cigarettes only Never cigs None 32.5969 66.0000
76:RAMANA M C-C NAmer Cigarettes +/ Never cigs None 6.7192 214.0000
77:RAMANA F C-C NAmer Cigarettes +/ Never cigs None 14.9178 170.0000
78:REID C C-C Auslia Any product Never any Sex, age +2 10.1800 37.5517
79:ROTUNN C C-C Europe Any product Never any Sex, age +1 11.1111 786.3231
80:RUANOR C C-C Europe Cigarettes +/ Never cigs None 10.9083 54.0000
81:RYLAND M C-C Europe Any product Never any None 15.1079 84.0000
82:RYLAND F C-C Europe Any product Never any None 8.9951 19.0000
83:SATIA C Prosp NAmer Cigarettes +/ Never cigs Sex, age 23.9600 291.4150
84:SIEMIA M C-C NAmer Cigarettes +/ Never cigs Age, race +3 23.4000 118.8127
85:SOBUE M C-C Asia Cigarettes +/ Never cigs None 5.0587 286.0000
86:SPEIZE F Prosp NAmer Cigarettes +/ Never cigs Age 20.0000 414.7098
87:STELL1 M C-C NAmer Cigarettes +/ Never cigs Age +2 50.0000 260.1669
88:STELL2 M C-C Asia Cigarettes +/ Never cigs Age +1 6.2500 101.8965
89:SUZUK2 C C-C SCAmer Any product Never any None 12.3667 34.0000
90:SVENSS F C-C Europe Any product Never any None 8.4608 30.0000
91:THOMPS C C-C NAmer Cigarettes only Never any Sex, age 38.4700 58.0965
92:TOMASE M C-C Europe Any product Never any Age +2 5.5000 270.7385
93:TSE M C-C Asia Any product Never any Age 7.6923 278.4106
94:TVERDA M Prosp Europe Cigarettes only Never cigs Age +1 16.1400 10.9891
95:WAKAI M C-C Asia Cigarettes +/ Never any Age +1 4.0500 49.9804
96:WAKAI2 M Prosp Asia Any product Never any Age +1 4.2300 268.5077
97:WANG2 C C-C Asia Cigarettes +/ Never cigs None 2.4557 11.0000
98:WYNDE3 M C-C NAmer Any product Never any None 10.7225 48.0000
99:WYNDE6 M C-C NAmer Cigarettes only Never any None 15.9905 534.0000
100:WYNDE6 F C-C NAmer Cigarettes only Never any None 10.9170 195.0000
101:WYNDE9 M C-C NAmer Any product Never any Age, race +2 20.7200 892.3798
102:WYNDE9 F C-C NAmer Any product Never any Age, race +2 19.0800 541.5278
103:YONG C Prosp NAmer Any product Never any None 7.4000 23.4085
104:YUAN2 C Prosp Asia Cigarettes +/ Never cigs Sex, age +2 5.8824 150.1292
105:ZHANG2 F Prosp NAmer Any product Never any Age +11 14.0400 20.9514
106:ZHOU2 C C-C NAmer Cigarettes +/ Never cigs None 11.0060 571.0000
a M = male, F = female, C = sexes combined. For study DORN block 29 is for age 55–64 and block 30 is for age 65–74.
b Prosp = prospective, C-C = case-control (including nested case-control).
c Auslia = Australasia, Multi = Multicountry, NAmer = North America, SCAmer = South or Central America.
d Any product = smokes cigarettes and/or pipes and/or cigars. Cigarettes +/ = smokes cigarettes with or without other products (pipes, cigars).
e Denominator of relative risk: never any = never any product, never cigs = never cigarettes.
f The number indicates the number of risk factors other than age, sex or race that were adjusted for: ANDERS: physical activity, education, BMI, waist circumference
alcohol, fruit consumption; BAYSSO: region; BHURGR: hospital; CHYOU: % predicted FEV1; DESTEF: residence, urban/rural, education; EPIC: centre; FRANCO: education,
access to social security; GAJALA: education, chewing tobacco, alcohol, centre; GAO: education; IARC: education, centre; JACOBS: cohort; JAMRO1: area of residence, country
of birth, education, marital status; JAMRO2: area of residence, country of birth, education, marital status; KUBIK2: residence, education; LEE: area, education, socioeconomic
status; LEE2: education; LEITZM: BMI, education, vigorous physical activity, usual activity, alcohol, fruit intake, vegetable intake, red meat intake, processed meat intake, total
energy intake; MAO: province, passive smoking, consumption of vegetables, consumption of vegetable juices, consumption of meat; MATOS: hospital; OLSEN: study; PARK:
tuberculosis; PETRAU: year of death; REID: time since ﬁrst asbestos exposure, cumulative asbestos exposure; ROTUNN: area; SIEMIA: occupation, income, respondent status;
STELL1: education, hospital; STELL2: education; TOMASE: year of birth, cohort; TVERDA: area; WAKAI: residence; WAKAI2: cohort; WYNDER9: BMI, education; YUAN2:
dialect group, year of interview; ZHANG2: education, BMI, moderate physical activity, alcohol, HRT use, fat, cereal ﬁber, betacarotene, vitamin A, vitamin C, vitamin E.
g Estimated pseudo-numbers by method of Hamling et al. (2008). Note that ﬁve blocks with less than 10 cases in quitters were not included in analysis. All were for
females, and they were from studies BECHER, CHOI, DEAN3, HIRAYA and WYNDER3.
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such combination being up to 5 years in studies FIELD, GARSHI,
SPEIZE and WAKAI. The RRs reveal an obvious trend for risk to de-
cline with increasing time quit. Thus, in all 106 blocks, the RR for
the longest time quit is less than for the shortest, and in 82
(77.4%) blocks, the RRs for quitters (ignoring current smokers) de-
crease strictly monotonically with increasing time quit. However,
it is clear that short-term quitting is associated with an increased
RR in many studies, with the RR for the ﬁrst quitting group higher
than that for current smokers in 39 (36.8%) of the 106 blocks, and
also higher in 17 (32.7%) of the 52 blocks in which the shortest-
term quitters were included in the current smokers. Long-term
quitters clearly also tend to have an increased risk compared to
never smokers. Thus, for the ﬁnal open-ended quit period, typically
associated with a midpoint of order 30 years quitting, the median
RR is 2.09, with 13 blocks having an RR of 5 or more, as compared
to 13 with an RR of 1.2 or less.
Additional ﬁle 3: ‘‘Full output’’ (downloadable from http://
www.pnlee.co.uk/downloads/ieslc3/LC_Quitting_Paper_Additional
Files.htm) gives complete details of the analyses carried out using
the negative exponential model, including the main analysis andthe two sensitivity analyses. For each analysis, the output
includes the 95% CI of the RR estimates shown in Table 3, the
estimates and standard errors of all the ﬁtted parameters, and
the observed and ﬁtted numbers of cases and controls at each level
for each block.
Table 4 compares the observed number of lung cancer cases
summed over blocks for never smokers, for current smokers and
for quitters (by time quit) with the corresponding ﬁtted numbers
for each of the three analyses. The main analysis ﬁts poorly, prin-
cipally due to underestimating the numbers of cases in short-term
quitters. This is because the negative exponential model assumes
that risk declines monotonically with time quit, so failing to model
the higher risk in short-term quitters than in current smokers seen
in many blocks. The ﬁt is much improved in sensitivity analysis S1,
where the estimate for the ﬁrst quitting group in each block is ig-
nored, but there is still some misﬁt, principally due to underesti-
mation of risk where the time quit is less than ﬁve years, some
studies showing increased risk for more than one level of short-
term quitting. The ﬁt is also much improved, compared to the main
analysis, in sensitivity analysis S2, where estimates relating to quit
periods with an upper limit of up to three years are counted as
Table 3
Relative risks (vs never smokers) for current smokers and quitters by time of quit for each block.
Block: study Time quit groupingsa Mean values Relative risks Mb
1:ALDERS 0, <3, 3, 10+ 0, 1.5, 6.5, 30 10.00, 18.10, 4.30, 3.20 M
2:ALDERS 0, <3, 3, 10+ 0, 1.5, 6.5, 30 4.55, 9.45, 2.95, 1.27 M
3:ANDERS 0, <6, 6, 11, 21, 31+ 0, 3, 8.5, 16, 26, 40 18.67, 11.60, 7.40, 3.20, 3.70, 1.00
4:ARMADA <1, 1, 6+ 0, 3.5, 28 13.68, 15.58, 5.10 M
5:BARBON 0, <5, 5, 15, 25+ 0, 2.5, 10, 20, 37.5 13.80, 13.90, 9.10, 6.80, 2.10 M
6:BAYSSO <2, 2–10, >10 0, 6, 30 15.60, 9.20, 2.90 M
7:BECHER <2, 2, 5, 10+ 0, 3.5, 7.5, 30 14.90, 15.00, 9.00, 4.00 M
8:BHURGR <2, 2, 5, 10, 15, 20+ 0, 3.5, 7.5, 12.5, 17.5, 35 33.33, 56.67, 30.00, 10.00, 6.67, 6.67
9:BROSS 0, <6, 6+ 0, 3, 28 5.92, 11.28, 2.44 M
10:BRUSKE 62, >2, 6, 11–21, >21 0, 4, 8.5, 16.0, 35.5 33.11, 13.40, 11.53, 8.57, 3.20 M
11:CAICOY 0, <1, 2, 6, 11, 16+ 0, 0.5, 4, 8.5, 13.5, 33 5.00, 30.38, 12.96, 4.99, 2.10, 2.64
12:CARPEN 0, <5, 5, 10, 15+ 0, 2.5, 7.5, 12.5, 32.5 32.89, 15.33, 13.54, 4.59, 5.50
13:CEDERL 0, <10, 10+ 0, 5, 29.5 7.81, 6.10, 1.10 M
14:CHOI 0, <5, 5, 10, 15+ 0, 2.5, 7.5, 12.5, 32.5 5.13, 2.85, 1.22, 1.27, 1.54
15:CHYOU 0, <15, 15+ 0, 7.5, 31.5 10.33, 3.80, 2.80 M
16:CPSI 0, <1, 1, 5, 10+ 0, 0.5, 3, 7.5, 30 13.77, 14.74, 8.09, 5.15, 1.28 M
17:CPSII 0, <1, 1, 3, 6, 11, 16+ 0, 0.5, 2, 4.5, 8.5, 13.5, 33 19.69, 48.45, 26.44, 18.83, 11.24, 8.69, 3.71 M
18:CPSII 0, <1, 1, 3, 6, 11, 16+ 0, 0.5, 2, 4.5, 8.5, 13.5, 33 12.97, 23.58, 15.36, 9.22, 4.71, 2.04, 2.06
19:DAMBER 0, <6, 6, 11+ 0, 3, 8.5, 30.5 9.60, 7.70, 4.30, 2.60 M
20:DEAN3 62, >2, 5, 9+ 0, 3.5, 7, 29.5 6.01, 4.82, 3.29, 2.04 M
21:DESTE3 0, <5, 5, 10, 15+ 0, 2.5, 7.5, 12.5, 32.5 11.19, 11.07, 7.75, 3.21, 2.15 M
22:DESTE4 0, <10, 10, 20+ 0, 5, 15, 35 12.60, 11.81, 6.00, 4.18 M
23:DESTEF 0, <5, 5, 10+ 0, 2.5, 7.5, 30 10.90, 9.00, 6.20, 2.80 M
24:DOLL 0, <10, 10, 20+ 0, 5, 15, 35 9.52, 6.51, 2.01, 3.03
25:DOLL 0, <10, 10+ 0, 5, 30 2.09, 2.21, 0.74 M
26:DOLL2 0, <5, 5, 10, 15+ 0, 2.5, 7.5, 12.5, 32.5 15.80, 16.00, 5.90, 5.30, 2.00 M
27:DORGAN 61, >1, 6, 10+ 0, 3.5, 8, 30 16.53, 12.46, 13.89, 5.66
28:DORGAN 61, >1, 10+ 0, 5.5, 30 10.60, 5.68, 2.10 M
29:DORN 0, <5, 5, 10, 15+ 0, 2.5, 7.5, 12.5, 29.5 13.52, 13.17, 7.92, 4.33, 2.33 M
30:DORN 0, <5, 5, 10, 15+ 0, 2.5, 7.5, 12.5, 32.5 9.03, 7.90, 5.95, 5.05, 2.32 M
31:EPIC 0, 610, >10, >20 0, 5, 15, 35 19.52, 6.01, 2.36, 1.27 M
32:EPIC 0, 610, >10, >20 0, 5, 15, 35 6.45, 2.63, 1.11, 1.30
33:FIELD <5, 5, 10, 20, 30+ 0, 7.5, 15, 25, 40 25.98, 14.20, 4.75, 1.99, 1.03 M
34:FRANCO 0, <5, 5, 15+ 0, 2.5, 10, 32.5 7.69, 9.46, 7.46, 3.00 M
35:FRANCO 0, <5, 5, 15+ 0, 2.5, 10, 32.5 3.45, 3.83, 2.24, 1.52 M
36:GAJALA 61, >1, >3, >10, >15 0, 2, 6.5, 12.5, 32.5 5.26, 3.42, 2.16, 1.68, 1.53 M
37:GAO 0, <5, 5, 10+ 0, 2.5, 7.5, 29.5 3.90, 6.90, 3.90, 1.10 M
38:GAO 0, <5, 5, 10+ 0, 2.5, 7.5, 29.5 2.90, 7.20, 3.90, 2.20 M
39:GAO2 <1, 1, 5, 10, 15, 20+ 0, 3, 7.5, 12.5, 17.5, 35 6.77, 5.14, 3.48, 3.83, 3.35, 1.38
40:GARSHI <5, 5, 15+ 0, 10, 32.5 7.70, 5.06, 3.20 M
41:GRAHAM 0, 61, >1, >5 0, 0.5, 3, 27.5 7.26, 35.79, 8.50, 2.59 M
42:HAMMO2 0, <5, 5, 10+ 0, 2.5, 7.5, 30 10.14, 10.99, 3.98, 3.45 M
43:HIRAYA 0, <5, 5, 10+ 0, 2.5, 7.5, 30 4.45, 2.03, 1.59, 1.38 M
44:IARC <2, 2, 10, 20, 30+ 0, 6, 15, 25, 40 25.00, 16.50, 6.75, 4.25, 2.00 M
45:IARC <2, 2, 10, 20, 30+ 0, 6, 15, 25, 40 9.09, 3.73, 1.73, 0.73, 1.18
46:JACOBS 0, <1, 1, 10+ 0, 0.5, 5.5, 24.5 3.95, 3.09, 1.45, 0.18 M
47:JAIN <2, 2, 10+ 0, 6, 30 15.91, 11.39, 3.26 M
48:JAIN <2, 2, 10+ 0, 6, 30 12.68, 7.54, 1.28 M
49:JAMRO1 0, <6, 6, 11, 21+ 0, 3, 8.5, 16, 35.5 21.92, 5.03, 10.09, 4.61, 1.98
50:JAMRO2 0, <6, 6, 11, 21+ 0, 3, 8.5, 16, 35.5 10.74, 10.62, 8.61, 6.97, 2.86 M
51:JOLY <1, 1, 5+ 0, 3, 27.5 15.64, 19.18, 7.68 M
52:JOLY <1, 1, 5+ 0, 3, 27.5 7.48, 12.93, 4.30 M
53:KAISE2 <2, 2, 11, 21+ 0, 6.5, 16, 35.5 8.00, 8.26, 3.14, 1.94 M
54:KAISE2 <2, 2, 11, 21+ 0, 6.5, 16, 35.5 14.14, 7.95, 4.37, 6.29
55:KHUDER 0, <5, 5, 15+ 0, 2.5, 10, 32.5 10.42, 9.61, 6.36, 3.97 M
56:KUBIK2 60.5, >0.5, 10, 20+ 0, 5.25, 15, 35 27.19, 19.11, 7.25, 4.52 M
57:KUBIK2 60.5, >0.5, 10, 20+ 0, 5.25, 15, 35 7.72, 8.10, 2.80, 1.72 M
58:LEE <1, 1, 6+ 0, 3.5, 28 3.45, 2.48, 1.53 M
59:LEE2 0, 64, >4, >12 0, 2, 8, 27 3.70, 20.00, 4.07, 1.00 M
60:LEITZM <1, 1, 5, 10+ 0, 3, 7.5, 30 32.37, 24.47, 17.56, 6.38 M
61:LEITZM <1, 1, 5, 10+ 0, 3, 7.5, 30 21.72, 14.86, 11.37, 3.93 M
62:LUBIN 62, >2, 5, 10+ 0, 3.5, 7.5, 30 3.64, 14.67, 3.33, 1.86 M
63:LUBIN2 0, <5, 5, 10, 15, 20, 25+ 0, 2.5, 7.5, 12.5, 17.5, 22.5, 37.5 10.38, 11.39, 7.81, 5.36, 3.74, 3.53, 2.10 M
64:LUBIN2 0, <5, 5, 10, 15, 20, 25+ 0, 2.5, 7.5, 12.5, 17.5, 22.5, 37.5 3.79, 3.86, 2.65, 1.36, 1.52, 1.57, 0.71
65:MAO 0, <11, 11, 20, 29+ 0, 5.5, 15.5, 24.5, 39.5 17.30, 14.50, 7.30, 3.50, 1.50 M
66:MAO 0, <11, 11, 20, 29+ 0, 5.5, 15.5, 24.5, 39.5 13.20, 11.80, 3.30, 1.60, 1.50 M
67:MATOS <1, 1, 6, 11+ 0, 3.5, 8.5, 30.5 10.00, 14.00, 9.00, 3.00 M
68:OLSEN 0, 610, >10 0, 5, 30 21.29, 16.00, 2.84 M
69:OSAKI 0, <5, 5, 10, 20+ 0, 2.5, 7.5, 15, 35 4.90, 2.80, 3.90, 1.90, 1.40
70:PAPADO 0, <3, 3, 10, 20+ 0, 1.5, 6.5, 15, 35 6.81, 19.56, 5.11, 2.09, 1.31 M
71:PARK <0.083c, 0.083, 3+ 0, 1.54, 26.5 2.27, 1.86, 1.30 M
72:PARK <0.083c, 0.083, 3+ 0, 1.54, 26.5 3.08, 3.11, 2.13 M
73:PETRAU <2, 2, 5, 10, 20+ 0, 3.5, 7.5, 15, 35 20.00, 22.80, 12.60, 7.80, 8.60 M
74:PEZZO2 <1, 1, 11+ 0, 6, 30.5 22.95, 15.07, 5.21 M
(continued on next page)
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Table 3 (continued)
Block: study Time quit groupingsa Mean values Relative risks Mb
75:PEZZOT <1, 1, 11+ 0, 6, 30.5 32.60, 16.27, 5.47 M
76:RAMANA <2, 2, 6, 11+ 0, 4, 8.5, 30.5 6.72, 5.05, 2.59, 1.21 M
77:RAMANA <2, 2, 6, 11+ 0, 6.5, 30.5 14.92, 18.00, 6.94 M
78:REID 0, <6, 6, 10, 20+ 0, 3, 8, 15, 35 10.18, 22.10, 9.30, 8.90, 1.90 M
79:ROTUNN <0.5, 0.5, 5–15, >15, >24 0, 2.75, 10, 19.5, 37 11.11, 16.56, 7.00, 3.44, 1.56 M
80:RUANOR <1, 1, 3, 11, 16+ 0, 2, 7, 13.5, 33 10.91, 19.25, 7.70, 8.40, 2.37
81:RYLAND <4, 4, 11, 16, 21+ 0, 7.5, 13.5, 18.5, 35.5 15.11, 9.85, 4.88, 3.97, 1.71 M
82:RYLAND <4, 4, 11, 16, 21+ 0, 7.5, 13.5, 18.5, 35.5 9.00, 3.26, 3.26, 1.18, 2.68
83:SATIA 0, <10, 10+ 0, 5, 30 23.96, 17.94, 5.77 M
84:SIEMIA 61, >1, >5, >10, >15 0, 3, 7.5, 12.5, 32.5 23.40, 13.90, 12.40, 8.00, 2.60 M
85:SOBUE <1, 1, 5, 10, 15, 20, 25+ 0, 3, 7.5, 12.5, 17.5, 22.5, 37.5 5.06, 4.79, 3.16, 3.04, 3.36, 2.83, 1.85
86:SPEIZE <5, 5, 10, 15, 20+ 0, 2.5, 7.5, 12.5, 17.5, 27.5 20.00, 12.80, 8.40, 5.40, 3.00, 1.80 M
87:STELL1 61, >1, 5, 10, 16+ 0, 3, 7.5, 13, 33 50.00, 25.00, 25.00, 20.00, 5.00
88:STELL2 61, >1, 5, 10, 16+ 0, 3, 7.5, 13, 33 6.25, 5.63, 5.00, 1.25, 1.25
89:SUZUK2 0, <6, 6, 11+ 0, 3, 8.5, 30.5 12.37, 7.23, 6.02, 1.97 M
90:SVENSS 62, >2, 11+ 0, 6.5, 30.5 8.46, 3.89, 1.84 M
91:THOMPS 62, >2, >5, >10, >15 0, 3.5, 7.5, 12.5, 32.5 38.47, 17.66, 19.50, 6.12, 2.09
92:TOMASE 0, <10, 10–19, >19 0, 5, 14.5, 34.5 5.50, 7.58, 2.54, 1.64 M
93:TSE <1, 1, 2, 3, 4, 5, 10, 15, 20+ 0, 1.5, 2.5, 3.5, 4.5, 7.5, 12.5, 17.5, 35 7.69, 13.38, 3.31, 3.92, 3.54, 2.15, 2.23, 2.00, 1.31
94:TVERDA 0, <1, 1, 5+ 0, 0.5, 3, 17 16.14, 2.77, 2.83, 1.34 M
95:WAKAI <5, 5, 10, 20+ 0, 7.5, 15, 35 4.05, 2.48, 3.63, 1.00
96:WAKAI2 0, <5, 5, 10, 15, 20, 25+ 0, 2.5, 7.5, 12.5, 17.5, 22.5, 37.5 4.23, 3.68, 2.52, 1.87, 1.24, 1.09, 0.59 M
97:WANG2 0, <4, 4+ 0, 2, 27 2.46, 2.35, 1.78 M
98:WYNDE3 <1, 1, 4, 7, 13+ 0, 2.5, 5.5, 10, 31.5 10.72, 9.33, 6.33, 3.47, 0.89 M
99:WYNDE6 <1, 1, 5, 10, 20, 30+ 0, 3, 7.5, 15, 25, 40 15.99, 17.37, 7.25, 6.11, 3.72, 1.87 M
100:WYNDE6 <1, 1, 5, 10, 20, 30+ 0, 3, 7.5, 15, 25, 40 10.92, 9.29, 4.81, 2.16, 1.65, 2.56
101:WYNDE9 0, <11, 11, 21+ 0, 5.5, 16, 35.5 20.72, 14.43, 7.43, 3.71 M
102:WYNDE9 0, <6, 6, 16+ 0, 3, 11, 33 19.08, 10.18, 6.68, 3.61 M
103:YONG 0, <10, 10+ 0, 5, 30 7.40, 6.30, 3.70 M
104:YUAN2 0, <1, 1, 5, 20+ 0, 0.5, 3, 12.5, 35 5.88, 5.35, 3.00, 2.18, 1.24 M
105:ZHANG2 <1, 1, 10, 20+ 0, 5.5, 15, 29.5 14.04, 5.48, 2.67, 0.55 M
106:ZHOU2 <1, 1, 6, 16, 31+ 0, 3.5, 11, 23.5, 40.5 11.01, 12.39, 7.23, 4.37, 2.97 M
a The ﬁrst group is considered as current smokers in analysis. Entries other than 0 for the ﬁrst group imply that short-term quitters were included among the current
smokers. <n Implies less than n if no previous 0, and less than n but greater than 0 otherwise (and similarly 6n for less than or equal to n). n – Implies greater than or equal to
n but less than the next number cited. >n – Implies greater than (but not equal) to n and less than the next number cited. n+ Implies greater than or equal to n.
b M indicates a strictly monotonic decline in RR with increasing time quit. This ignores the ﬁrst RR, which is for current smokers.
c 0.083 represents 1 month (study PARK).
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estimation of risk where the time quit is less than ﬁve years. The ﬁt
for sensitivity analysis S2 is less good than for S1, though both
analyses ﬁt the trend for ﬁve or more years quitting quite
accurately.
Table 5, gives, for each block, ﬁtted values of H (in years) for
the main and the two sensitivity analyses. Estimates are gener-
ally quite similar for the different analyses. This similarity is par-
ticularly marked comparing main vs. S2, partly because someTable 4
Time quit – observed and ﬁtted lung cancers smoking for the main analysis and the two
Time of quitting smoking Main analysis
Observedc Fittedd
Current smokers 48238.69 48727.87
<2 1398.55 937.46
2 to <5 5527.83 5288.65
5 to <10 6656.45 6747.65
10 to <15 1953.08 2070.34
15 to <20 1062.00 1111.60
20+ 6238.26 6097.21
Never smokers 6081.82 6117.45
Total 78087.74 78088.22
Fit statistice 338.72
a Omitting the estimate in each block with the shortest quitting period.
b Counting estimates with an upper limit of quitting time of up to 3 years as applying
c Observed pseudo-number of lung cancer cases, summed over block.
d Fitted pseudo-number of lung cancer cases, summed over blocks. For each study, the
ﬁtted relative risks by amount smoked, derived from the ﬁtted value of b1.
e Based on summation of (observed–ﬁtted)2/ﬁtted, the summation also including term
be considered to be approximately chi squared distributed on 12 df and is signiﬁcant atblocks had no estimate with an upper quit time of less than
three years (so the data considered were identical), and partly
because numbers of cases in short-term quitters were much less
than in current smokers. Comparing main vs. S1, there were
some exceptions, such as blocks 15 (CHYOU) and 25 (DOLL fe-
males) where there were only two levels of quitting and removal
of one level materially affected the estimate of H. The meta-anal-
ysis estimates of H are quite close – 9.74 years for main,
9.93 years for S1 and 9.72 for S2.sensitivity analyses, with b1 ﬁtted separately for each block.
Sensitivity S1a Sensitivity S2b
Observedc Fittedd Observedc Fittedd
48238.69 48129.84 49930.87 49955.16
651.32 562.15 5234.21 5025.78
3058.25 3210.50 6656.45 6737.56
1786.81 1858.78 1953.08 2063.52
1062.00 1098.86 1062.00 1110.72
6238.26 6095.11 6238.26 6084.73
6081.82 6119.85 6081.82 6121.35
68048.21 68048.46 78087.74 78088.30
31.84 52.50
to current smokers.
ﬁtted number of cases for each block is calculated from the numbers at risk and the
s for the observed and ﬁtted total number of controls (not shown). The statistic can
p < 0.001 for each analysis.
Table 5
Estimated half-life (H), in years, and goodness-of-ﬁt statistic for each block for the main and sensitivity analyses.
Block: study Half-life Half-life Half-life p(Fit)a p(Fit)a p(Fit)a
Main Sensitivity S1b Sensitivity S2c Main Sensitivity S1b Sensitivity S2c
1:ALDERS 12.1267 13.4882 11.2629 0.0014 NS NS
2:ALDERS 7.8565 7.8296 5.1869 0.0001 NS NS
3:ANDERS 6.1686 6.3694 6.1686 (0.0599) NS (0.0599)
4:ARMADA 16.6022 17.1966 16.6022 NS NS NS
5:BARBON 13.0964 13.1111 13.0964 NS NS NS
6:BAYSSO 10.3085 10.1975 10.3085 NS NS NS
7:BECHER 13.2887 13.3128 13.2887 NS NS NS
8:BHURGR 12.1120 12.2341 12.1120 NS NS NS
9:BROSS 17.4466 15.7532 17.4466 0.0002 NS 0.0002
10:BRUSKE 8.6413 8.5171 8.6413 NS NS NS
11:CAICOY 11.0125 18.0490 10.5678 0.0001 NS NS
12:CARPEN 10.2816 10.0211 10.2816 0.0140 0.0225 0.0140
13:CEDERL 7.3252 4.8443 7.3252 NS NS NS
14:CHOI 1.9820 1.4961 1.9820 NS NS NS
15:CHYOU 4.1832 13.2694 4.1832 NS NS NS
16:CPSI 4.4120 4.3896 4.3769 NS NS NS
17:CPSII 9.3651 11.2607 9.2621 0.0000 0.0000 0.0000
18:CPSII 4.4851 4.5121 4.3183 0.0000 0.0000 0.0021
19:DAMBER 12.0188 12.0162 12.0188 NS NS NS
20:DEAN3 12.0270 12.1740 12.0270 NS NS NS
21:DESTE3 9.1937 9.1527 9.1937 NS NS NS
22:DESTE4 17.1107 16.8260 17.1107 NS NS NS
23:DESTEF 11.5340 11.5753 11.5340 NS NS NS
24:DOLL 7.0351 4.2057 7.0351 NS NS NS
25:DOLL 11.4780 1.2604 11.4780 NS NS NS
26:DOLL2 6.6955 6.6920 6.6955 NS NS NS
27:DORGAN 17.4603 17.2786 17.4603 NS NS NS
28:DORGAN 9.1072 9.6027 9.1072 NS NS NS
29:DORN 8.5012 8.3564 8.5012 NS NS NS
30:DORN 12.3213 12.3225 12.3213 NS NS NS
31:EPIC 2.8707 3.8932 2.8707 NS NS NS
32:EPIC 2.7999 2.4789 2.7999 NS NS NS
33:FIELD 5.7875 5.4009 5.7875 NS NS NS
34:FRANCO 19.1773 19.4930 19.1773 NS NS NS
35:FRANCO 13.3174 13.4370 13.3174 NS NS NS
36:GAJALA 3.3551 3.5514 3.7280 NS NS NS
37:GAO 12.4845 9.0011 12.4845 0.0322 NS 0.0322
38:GAO 55.6472 55.7740 55.6472 NS NS NS
39:GAO2 9.7612 9.8168 9.7612 NS NS NS
40:GARSHI 19.4429 20.2283 19.4429 NS NS NS
41:GRAHAM 14.3198 14.8094 12.3370 0.0000 NS NS
42:HAMMO2 13.9593 13.4477 13.9593 (0.0544) NS (0.0544)
43:HIRAYA 1.6128 2.9459 1.6128 NS NS NS
44:IARC 8.0526 7.9508 8.0526 NS NS NS
45:IARC 3.9393 4.0202 3.9393 NS NS NS
46:JACOBS 2.6635 2.6844 2.6984 0.0007 0.0008 0.0008
47:JAIN 11.0255 11.0217 11.0255 NS NS NS
48:JAIN 6.0883 5.5836 6.0883 NS NS NS
49:JAMRO1 7.2356 6.8732 7.2356 0.0068 NS 0.0068
50:JAMRO2 14.8085 14.9494 14.8085 NS NS NS
51:JOLY 24.1769 24.3078 24.1769 NS NS NS
52:JOLY 28.2325 28.1838 28.2325 NS NS NS
53:KAISE2 11.8784 10.7066 11.8784 NS NS NS
54:KAISE2 14.3477 15.7936 14.3477 NS NS NS
55:KHUDER 18.9119 19.0238 18.9119 NS NS NS
56:KUBIK2 11.1162 11.1174 11.1162 NS NS NS
57:KUBIK2 10.2120 8.9779 10.2120 NS NS NS
58:LEE 11.7362 12.6770 11.7362 NS NS NS
59:LEE2 6.7555 8.1073 6.7555 0.0000 (0.0680) 0.0000
60:LEITZM 12.0066 11.9281 12.0066 0.0006 0.0013 0.0006
61:LEITZM 10.6058 10.5215 10.6058 0.0043 0.0454 0.0043
62:LUBIN 24.3416 19.7411 24.3416 0.0003 NS 0.0003
63:LUBIN2 11.7589 11.7201 11.7589 0.0023 NS 0.0023
64:LUBIN2 7.2168 6.6730 7.2168 NS NS NS
65:MAO 9.0615 9.1776 9.0615 NS NS NS
66:MAO 6.8153 6.2826 6.8153 0.0361 NS 0.0361
67:MATOS 14.7242 14.5766 14.7242 NS NS NS
68:OLSEN 8.6985 8.6630 8.6985 NS NS NS
69:OSAKI 8.4685 8.9747 8.4685 NS NS NS
70:PAPADO 7.4155 7.7069 7.1238 NS NS NS
71:PARK 12.1063 12.5776 12.9593 NS NS NS
72:PARK 30.3041 30.3247 30.2660 NS NS NS
73:PETRAU 20.7971 20.8536 20.7971 NS NS NS
(continued on next page)
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Table 5 (continued)
Block: study Half-life Half-life Half-life p(Fit)a p(Fit)a p(Fit)a
Main Sensitivity S1b Sensitivity S2c Main Sensitivity S1b Sensitivity S2c
74:PEZZO2 12.7539 12.8002 12.7539 NS NS NS
75:PEZZOT 10.5174 10.8122 10.5174 NS NS NS
76:RAMANA 5.1311 4.7313 5.1311 NS NS NS
77:RAMANA 24.0631 24.8373 24.0631 NS NS NS
78:REID 14.3401 14.5916 14.3401 NS NS NS
79:ROTUNN 9.2099 9.5414 9.2099 0.0019 NS 0.0019
80:RUANOR 12.4015 12.9928 12.2041 NS NS NS
81:RYLAND 8.2574 8.0174 8.2574 NS NS NS
82:RYLAND 6.0650 9.0079 6.0650 NS NS NS
83:SATIA 13.3345 13.2330 13.3345 NS NS NS
84:SIEMIA 7.8754 8.1150 7.8754 NS NS NS
85:SOBUE 15.4482 15.2974 15.4482 NS NS NS
86:SPEIZE 5.7164 5.7550 5.7164 NS NS NS
87:STELL1 9.4695 9.1670 9.4695 NS NS NS
88:STELL2 6.2239 6.1206 6.2239 NS NS NS
89:SUZUK2 8.3630 8.4017 8.3630 NS NS NS
90:SVENSS 8.7704 9.6910 8.7704 NS NS NS
91:THOMPS 5.8148 5.7630 5.8148 NS NS NS
92:TOMASE 12.8670 10.6380 12.8670 0.0005 NS 0.0005
93:TSE 2.9336 2.8928 3.4662 NS NS NS
94:TVERDA 0.1426 0.9512 0.9909 NS NS NS
95:WAKAI 14.1505 15.3847 14.1505 NS NS NS
96:WAKAI2 6.3855 6.2583 6.3855 NS NS NS
97:WANG2 29.7559 29.8014 30.2173 NS NS NS
98:WYNDE3 5.2654 5.1307 5.1843 NS NS NS
99:WYNDE6 9.4782 9.5254 9.4782 NS NS NS
100:WYNDE6 5.3865 5.2444 5.3865 NS NS NS
101:WYNDE9 11.9114 11.8770 11.9114 NS NS NS
102:WYNDE9 12.0176 11.4468 12.0176 0.0001 (0.0834) 0.0001
103:YONG 23.5414 24.0942 23.5414 NS NS NS
104:YUAN2 5.5176 5.5170 5.5354 (0.0836) (0.0841) (0.0870)
105:ZHANG2 4.2200 4.7755 4.2200 NS NS NS
106:ZHOU2 15.3767 15.9984 15.3767 NS NS NS
Meand 9.7377 9.9314 9.7221
a NS indicates pP 0.1. p Values in the range 0.05 6 p < 0.1 are shown in brackets.
b Omitting the estimate in each block with the lowest quitting period.
c Counting estimates with an upper limit of quitting time of up to 3 years as applying to current smokers.
d The inverse-variance weighted mean of log H, converted back to the original scale.
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three analyses. As expected from the results in Table 4, fewer mis-
ﬁts are seen for the sensitivity analyses than for the main analysis.
Nevertheless there were some blocks where even S1 showed mis-
ﬁt. The most marked (p < 0.01) were for four blocks. For blocks 17
(CPS II males) and 18 (CPS II females) this was because there was
little evidence of decline up to six years of quitting. For block 46
(JACOBS), this was due to the longest-term quitters (10+ years)
having a markedly reduced risk compared to never smokers (RR
0.18, 95% CI 0.07–0.48). For block 60 (LEITZM males), the misﬁt
was due to the relatively high RR in the longest-term quitters given
the size of the reduction in risk for shorter-term quitters, and the
block being based on a large number of cases in quitters (see
Table 2).
Table 6 shows the results of inverse-variance weighted simple
regression analysis of log H based on analysis S1. Highly signiﬁcant
(p < 0.001) variation is seen by sex, H being lower for females than
for either males or where risk was not separately estimated for
males and females, and is also seen by age with H increasing with
increasing midpoint age. Variation is also highly signiﬁcant
(p < 0.001) by publication year, due to higher estimates for the ear-
liest and latest groups (up to 1990 and from 2006) and lower esti-
mates for the other groups. There is also some variation (p < 0.01)
by number of cases in quitters, smaller studies having somewhat
lower estimates. The same four factors also showed signiﬁcant var-
iation in the main analysis and sensitivity analysis S2 (results not
shown).
Forward stepwise regression analyses were also conducted (re-
sults not shown). For sensitivity analysis S1, the factors included inturn were midpoint age (p < 0.001), sex (p < 0.001), number of
cases in quitters (p < 0.05) and product smoked (p < 0.05). The
direction of effect for midpoint age, sex and number of cases in
quitters was the same as shown in Table 6, the association with
product smoked due to a somewhat lower estimates of H for ciga-
rette only smoking. Publication year, highly signiﬁcant (p < 0.001)
in the simple regression analysis, was not included in the ﬁnal for-
ward stepwise model. In contrast, in the forward stepwise analyses
for the main analysis and sensitivity analysis S2, publication year
was the ﬁrst factor included in the model, and the ﬁnal models
did not include midpoint age or number of cases in quitters, but
did include, in turn, sex, continent, study type and current smoker
RR.
Fig. 1 presents the predicted excess risk relative to current
smokers, based on estimates of H, overall and by sex, derived from
sensitivity analysis S1.4. Discussion
4.1. Introduction
Our earlier review (Lee et al., 2012a) based on studies of smok-
ing and lung cancer published before the year 2000, clearly showed
that the excess risk decreases with time quit, consistent with ear-
lier reviews (International Agency for Research on Cancer, 2007;
US Surgeon General, 1979). Here we extend the analysis to more
recent studies, and quantify this decline, using the negative expo-
nential model.
Table 6
Time quit – inverse-variance weighted simple regression analyses of log H based on sensitivity analysis S1.
Factor Level n H (95% CI)a pb
All 106 9.93 (9.31–10.60)
Sex Male 62 10.71 (9.93–11.54) <0.001
Female 27 7.92 (7.00–8.96)
Combinedc 17 10.51 (8.74–12.64)
Study type Case-control 78 9.98 (9.10–10.95) NS
Prospective 28 9.88 (9.02–10.84)
Continent North America 40 10.20 (9.44–11.01) NS
Europe 32 9.10 (7.96–10.40)
Asia 19 7.32 (4.91–10.01)
Other 15 11.96 (9.01–15.87)
Publication yeard <1991 22 12.32 (9.83–15.45) <0.001
1991–95 19 9.69 (7.89–11.91)
1996–2000 17 8.12 (7.02–940)
2001–05 19 8.85 (7.81–10.03)
2006–11 29 11.09 (10.12–12.15)
Producte Any product 40 10.45 (9.05–12.06) NS
Cigarettes +/ 52 10.20 (9.40–11.08)
Cigarettes only 14 8.62 (7.43–10.00)
Unexposed Never cigarettes 39 9.60 (8.83–10.44) NS
Never any product 67 10.44 (9.43–10.57)
Grouped midpoint age <50 15 6.98 (5.98–8.16) <0.001
50–59 68 10.39 (9.45–11.42)
60–69 19 10.60 (9.70–11.58)
70+ 4 12.99 (8.15–20.69)
Current smoker RR <4 12 6.64 (3.36–13.16) NS
4–7.9 26 9.37 (6.95–12.62)
8–15.9 42 9.61 (8.45–10.94)
16+ 26 10.15 (9.38–10.98)
Cases in quitters <100 47 8.37 (6.74–10.38) <0.01
100 to <250 35 9.91 (8.51–11.54)
250 to <500 13 7.66 (6.54–8.98)
500 to <1000 7 10.64 (9.38–12.07)
1000+ 4 10.94 (9.90–12.08)
a The inverse-variance weighted mean of log H, converted back to the original scale (in years).
b Probability values for factor considered, presented as <0.001, <0.01, <0.05, <0.1 or NS (pP 0.1). The probability level is calculated based on the difference in deviance
between the model with a common estimate of H and the model with a separate estimate of H ﬁtted for each level of the factor studied.
c Blocks where risk was not separately estimated for males and females.
d Of principal publication for the study.
e Any product = smokes cigarettes and/or pipes and/or cigars. Cigarettes +/ = smokes cigarettes with or without other products (pipes, cigars).
Years quit smoking. 

























Fig. 1. Years quit smoking. Predictions of the negative exponential model overall and by sex. Percentage excess risk, 100 exp (t loge 2/H), is plotted against time quit (range
0–40 years) as estimated from data for the whole population (H = 9.9314), males (H = 10.4646), females (H = 7.7920) and sexes combined (H = 10.2287). H is the half-life: the
time at which the excess risk is half that associated with continued smoking. The estimates were derived from sensitivity analysis S1.
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and former smokers (by time quit), using methodology developed
when analyzing similar data for IHD (Lee et al., 2012b). Here the
excess risk for quitters for t years, as a proportion of the excess risk
for continuing smokers, is estimated as exp (t loge 2/H), where H is
the half-life. The shape of the ﬁtted dose-relationship is illustrated
in Fig. 1, and the extent to which the model ﬁts the overall pattern
of response is shown in Table 4. While the model did not ﬁt the
shape of the relationship well, failing to explain the increased risk
in short-term quitters, the misﬁt was substantially reduced in the
sensitivity analyses which made allowance for reverse causation
(discussed further below). Interestingly, however, allowance for re-
verse causation little affected the overall estimate of H.
Inverse-variance weighted analyses were also carried out to
identify sources of heterogeneity. It proved difﬁcult to clearly iden-
tify meaningful major sources of variation, though there was evi-
dence that estimates of H were higher in males than females and
increased with increasing midpoint age of the subjects.
Below we discuss issues relating to the interpretation of these
ﬁndings.
4.2. Adequacy of literature search and publication bias
Many studies identiﬁed come from the IESLC database used in
our earlier review (Lee et al., 2012a). As that review made clear,
the searches were extremely comprehensive, though limited to pa-
pers published before 2000 and studies of 100 cases or more. We
also used more recent data, though time and cost limitations pre-
cluded searching quite as thoroughly as before. Thus we did not
search for references cited in papers identiﬁed, or in reviews other
than that by IARC (International Agency for Research on Cancer,
2007). Nevertheless, if we had missed a few studies, this is unlikely
to have materially affected our conclusions. Publication bias was
discussed earlier (Lee et al., 2012a), evidence for its existence being
considered not strong. Where associations are weak, there is con-
cern that the probability of dose–response results being published
might depend on the strength of the overall relationship seen. This
has been clearly demonstrated for environmental tobacco smoke
and lung cancer (Fry and Lee, 2000), but seems less relevant here,
where the association with smoking is so strong. Nevertheless, it
remains possible that researchers may be less likely to publish re-
sults by time quit where little trend is seen.
There are various reasons why the ﬁtted relationship of quitting
to lung cancer might not accurately relate to the true relationship.
4.3. Misclassiﬁcation of smoking status
It is well-documented (Lee, 1988; Lee and Forey, 1995) that
some subjects deny current or past smoking habits, thereby
increasing the apparent risk of lung cancer in reported never smok-
ers and biasing downwards the estimated RR associated with
smoking. Such misclassiﬁcation is difﬁcult to adjust for, as it varies
by aspects of study design, the way questions are asked and also by
sex, age, location and other demographic variables.
In prospective studies there is an additional problem, especially
in studies with long-term follow-up, where re-interviews are not
usually carriedout toupdate smoking status. In particular somesub-
jects classiﬁed at baseline as current smokers may quit during fol-
low-up, while some classiﬁed as ex-smokers may resume smoking.
4.4. Updating of time quit
Another problem in prospective studies concerns the categori-
zation of quitters by time quit. In most analyses presented, risk is
simply related to time quit as reported at baseline. Thus a subject
in a prospective study who is classiﬁed at baseline as having quitfor 5–9 years may still be counted as having quit for 5–9 years at
time of lung cancer onset, which may occur many years later. If risk
declines monotonically with actual time quit, H will therefore be
underestimated by the use of time quit as recorded at baseline.
The extent of this bias is difﬁcult to estimate, but will clearly in-
crease with increasing time of follow-up, though it will be compen-
sated to some extent by bias in the opposite direction if some of
the quitters resume smoking during follow-up. It is relevant to
note that estimates of H were actually very similar for case-control
studies and prospective studies, as shown in Table 6.
4.5. Reverse causation
There is clear evidence that risk in short-term quitters may ex-
ceed that in current smokers. This is assumed (International
Agency for Research on Cancer, 2007) to be due to reverse causa-
tion. Some authors have combined short-term quitters with cur-
rent smokers in analysis to try to avoid this bias. Our sensitivity
analysis suggests that reverse causation has little effect on the esti-
mated value of H, whether we excluded data for the earliest quit
time from each block, or counted as current smokers all RRs within
a block which related to a quit time of up to three years. This is
probably due partly to the relatively small number of short-term
quitters (as compared to current smokers), and partly to the esti-
mate of H depending more on where the observed excess risk curve
actually declines to half that from current smoking than on the
precise shape of the curve shortly after quitting.
4.6. Estimating midpoints of ranges
The statisticalmethods used require an estimate of themidpoint
year of time quit for each period of quitting.We have not attempted
sensitivity analyses to gain insight into the effect that our proce-
dures for deﬁning midpoints had on the ﬁtted models. For IHD and
time quit (Lee et al., 2012b), using alternative midpoints for the
open-ended ﬁnal interval little affected on the estimates of H.
4.7. Use of pseudo-numbers
Our methodology requires knowledge, for each block, of the
number of cases and the numbers of controls (or at risk) in each
smoking group. As such data are often not provided, and indeed
for covariate-adjusted data are only a hypothetical concept, we
used the method of Hamling et al. (2008) to estimate a block of
pseudo-numbers corresponding exactly to the reported RRs and
CIs. Using pseudo-numbers has been shown (Orsini et al., 2012)
to allow accurate estimation of RRs and CIs relative to a different
base group from that used originally, and we believe should pro-
vide an adequate basis for our model ﬁtting.
4.8. Adjustment for other smoking variables
All our analyses compare risk relative to never smokers, with all
the RRs in any block adjusted for the same set of variables. As RRs
relative to never smokers cannot be adjusted for other smoking
variables, we necessarily restricted attention to estimates adjusted
for age and non-smoking characteristics. This is in some ways
unfortunate as, for example, early quitters may smoke less per
day than late quitters. In theory one could study the extent of such
bias based on studies which present results on quitting separately
for heavier and lighter smokers. However, few studies present such
data and we made no attempt to investigate this.
4.9. Use of simple models based on published results
We have restricted attention to a model of a simple functional
form, partly as it is much easier to explain results and conduct
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expressed in terms of a single parameter (here H). Also it is doubt-
ful whether the numerous data uncertainties justify a more com-
plex approach. Such an approach is better conducted using
individual person data from large studies, using models which
simultaneously account for amount smoked and duration of smok-
ing, so allowing a theoretically more precise estimation of H. As
many studies were old with the data quite likely inaccessible, we
made no attempt to obtain individual data sets.
4.10. Model ﬁt
Some comments should also be made about goodness-of-ﬁt to
the model studied and the factors that affect it. As expected, there
was misﬁt due to reverse causation, but this was substantially re-
duced (see Table 4) in the sensitivity analyses, where the model
described quite well the shape of the decline in excess risk follow-
ing quitting. Although alternative approaches to deal with reverse
causation seem possible, the consistency of the overall estimate of
H in all three analyses lends reassurance to the conclusion that the
data are well described by a negative exponential model with H
estimated as about 10 years. While there are blocks where the pat-
tern of results misﬁts the exponential model, it seems difﬁcult to
adapt the model to ﬁt these blocks better without other blocks
being ﬁtted worse. This is particularly true for the block (46:JA-
COBS) where long-term quitters had a risk much lower than seen
in never smokers, an observation not evident in other blocks,
which generally show a higher risk. Note that a value of H of
10 years implies that the excess risk, as a percentage of the current
smoker risk, is 25% at 20 years of quitting, 12.5% at 30 years and
6.25% at 40 years, the model predicting an asymptotic decline to
zero excess risk.
4.11. Sources of heterogeneity
We carried out inverse-variance weighted regression analyses
to attempt to determine sources of heterogeneity. While some of
the factors (e.g. age and sex) could be better evaluated using
pooled analyses based on individual person data, and problems
arise due to correlations between the variables studied, our analy-
ses should be able to highlight major sources. Sex and age were the
major sources of heterogeneity, with females having a lower H
than males (7.92 vs. 10.71 years for sensitivity analysis S1) and H
increasing with increasing age. Notwithstanding this heterogeneity
one may still draw the general conclusion that H is consistently
estimated at around 10 years in subsets of the data by a range of
factors.
4.12. Comparison with some previous work
The recent Monograph on ‘‘reversal of risk after quitting smok-
ing’’ (International Agency for Research on Cancer, 2007) included
a chapter on lung cancer. It presented results from numerous stud-
ies, concluding that the risk of lung cancer is less in quitters than in
otherwise similar current smokers, that the lower lung cancer risk
in quitters becomes apparent within ﬁve to nine years after quit-
ting, that the reduction becomes more apparent with increasing
time of quit, and that the risk never returns to that of never smok-
ers even after a long period of abstinence, all conclusions consis-
tent with our ﬁndings. However no attempt was made to model
the data, nor estimate the time at which the excess risk reaches
a half of that seen in continuing smokers. Attempts have been
made to quantify the risk more precisely. For example, the US Sur-
geon General (1990) stated that ‘‘after 10 years of abstinence, the
risk of lung cancer is about 30–50% of the risk for continuing smok-
ers; with further abstinence, the risk continues to decline.’’ How-ever, we are not aware of attempts to use the negative
exponential model to formally model the extent of the decline in
excess risk following quitting.
4.13. Extension to the model
As we noted earlier for IHD (Lee et al., 2012b), quitting can be
viewed as switching from an exposure of F = 1 unit (that of current
smoking) to an exposure of F = 0 units (that of quitters), and re-
expressing the excess risk at time t as F + (1F) exp (t loge 2/H)
allows for the possibility of modelling the effect of switching to
an exposure intermediate between 0 and 1. Given the estimate of
H from this paper, and an estimate of F, this allows estimation of
the effects of switching to a reduced number of cigarettes per
day, or of switching to a reduced exposure product.5. Conclusions
It is possible to describe the observed shape of the relationship
between time quit and lung cancer quite accurately using the rel-
ative simple negative exponential model. The model does not ex-
plain the observed increase in lung cancer risk in short-term
quitters due to reverse causation, but still appears to estimate
the half life (H) quite reliably as about 10 years, based on the sen-
sitivity analyses conducted. Though there is some evidence of mis-
ﬁt to the model for some data blocks, this seems mainly due to
unusual patterns of response difﬁcult to ﬁt with plausible models,
or to different blocks showing differing shapes of the relationship.
The main limitation of the model relates to the data to which it was
ﬁtted. Misclassiﬁcation of smoking status is likely to produce bias,
as is failure to update smoking habits during follow-up in prospec-
tive studies, and failure to adjust for other indices of dose. Never-
theless, the model characterizes the observed relationship of lung
cancer to time quit more fully than previously attempted.Conﬂict of interest
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